Richter Gedeon Nyrt. stock (HU0000123096): shares hover near HUF 12,600 as Budapest blue chip consolidates

Richter Gedeon Nyrt. shares started June trading on the Budapest Stock Exchange with the stock moving in a narrow band around HUF 12,600, extending the consolidation phase seen in late May for the Hungarian blue-chip pharmaceutical name.

According to a technical overview of the BUX index heavyweights published on 06/01/2026 by Világgazdaság, Richter traded in a consolidation zone between HUF 12,450 and HUF 12,600 at the end of May, signaling that, after earlier gains this year, the price has been moving sideways rather than in a clear new trend leg.Világgazdaság as of 06/01/2026

The stock is part of the BUX benchmark index in Hungary and trades under the ticker RICHTER on the Budapest Stock Exchange, giving Hungarian and regional investors direct exposure to one of Central and Eastern Europe's leading pharmaceutical manufacturers.Gedeon Richter investor relations as of 06/01/2026

On 06/01/2026, shares were quoted around HUF 12,650 on the Budapest bourse, in line with the late-May range flagged by domestic market commentary, suggesting that investors are currently weighing next catalysts such as macro conditions, regulatory developments and the next round of quarterly figures before committing to a new direction.Investing.com as of 06/01/2026

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

Richter Gedeon Nyrt.: core business model

The group operates as an integrated pharmaceutical manufacturer and developer, with revenue largely stemming from research-based branded therapies in women’s health and central nervous system disorders complemented by generics and contract manufacturing activities.

What banks and research houses say about Richter Gedeon Nyrt.

No verified analyst coverage was identified at the time of publication.

Conclusion

Richter Gedeon Nyrt. is beginning June with its shares fluctuating in a tight HUF 12,450 to HUF 12,600 corridor on the Budapest Stock Exchange, reflecting a consolidation phase after earlier gains in 2026. The absence of fresh earnings data or newly published broker research on 06/01/2026 places the focus on technical levels and upcoming company newsflow as potential catalysts for the next move in the Hungarian pharmaceutical stock. For investors watching Central and Eastern European equities, the stock’s current sideways pattern will likely remain key until a new fundamental or market-driven trigger emerges.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.